MSL
TGTX icon

Mackay Shields LLC’s TG Therapeutics TGTX Stock Holding History

Mackay Shields LLC’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40,200
Closed -$1.94M – 1276
2021
Q1 		$1.94M Sell
40,200
-34,100
-46% -$1.64M 0.01% 780
2020
Q4 		$3.87M Buy
74,300
+2,800
+4% +$94.6K 0.03% 566
2020
Q3 		$1.91M Buy
71,500
+12,700
+22% +$292K 0.01% 809
2020
Q2 		$1.15M Buy
+58,800
New +$947K 0.01% 977
2018
Q4 		– Sell
-40,600
Closed -$227K – 1400
2018
Q3 		$227K Buy
40,600
+12,400
+44% +$142K ﹤0.01% 1075
2018
Q2 		$371K Buy
+28,200
New +$388K ﹤0.01% 1138

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Mackay Shields LLC's TGTX Position: Q2 2021 in Review

Mackay Shields LLC sold out of TG Therapeutics (TGTX) in Q2 2021, closing a stake of 40,200 shares — an estimated $1.94M sold.

Mackay Shields LLC first reported a position in TGTX in Q2 2018 and held it in 6 quarters. The position peaked at $3.87M in Q4 2020. 237 funds tracked by Wall St. Rank hold TGTX as of Q2 2021.

  • Mackay Shields LLC reported no remaining TG Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 40,200 TG Therapeutics shares in Q2 2021, an estimated $1.94M.
  • Mackay Shields LLC first reported a position in TG Therapeutics in Q2 2018 and held it in 6 quarters.
  • Mackay Shields LLC's TG Therapeutics position peaked at $3.87M in Q4 2020.
  • 237 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.